

# ALLANTOIN — ITS PROPERTIES AND USES

By A. M. POSNER, B.Sc., Ph.D.

THE FOLLOWING is a critical survey of the literature dealing with the therapeutic and cell proliferant action of allantoin (glyoxyl-diureide).

## HISTORICAL

The use of infusions of the common comfrey root to promote healing has been known for several hundred years. Macalister in 1912<sup>1</sup> reported his observations on the healing power of this substance and in addition submitted some of the root to chemical analysis. Amongst other substances isolated was allantoin, which was present to the extent of 0.8 per cent.

Macalister then successfully treated three refractory ulcers with a solution of synthetic allantoin. Many other cases of a similar nature were also reported.<sup>2</sup>

The apparent beneficial effects of maggots growing in open wounds has also been known for a long time, and Baer,<sup>3</sup> during and immediately after the First World War, developed a maggot therapy for the treatment of refractory wound infections.

Robinson,<sup>4</sup> in a critical examination of maggot therapy, showed that amongst other substances produced by the maggots was allantoin. He was able to obtain successful healing of severe osteomyelitis cases using allantoin; however, the rate of healing was not so rapid as when maggots were used.

Robinson and Norwood<sup>5</sup> demonstrated by dissection and culturing techniques that pyogenic bacteria are destroyed in the alimentary tract of the maggot. Thus bacteria taken in by the feeding maggot will be destroyed. They also showed<sup>6</sup> that the extract derived from maggots had no effect on bacteria cultures. It is possible that some of the active principle was destroyed during the maceration process.

Livingston<sup>7,8</sup> treated 415 cases of osteomyelitis, ulcers and similar conditions with living maggots and maggot extract, and 605 cases by extract only. From 60 to 100 per cent of the cases showed clinical improvement through growth stimulation and a pathogenic bacterial inhibition.

The maggot extract was shown to contain sulphhydryl groups, allantoin, calcium, cysteine, glutathione and embryonic growth-promoting substances. Maggot therapy exhibits the following features.

1. Thorough surgical removal of diseased area.
2. The wound is actively sterilised by the maggots, which physically remove micro-organisms by ingestion.
3. The proteolytic activity of the maggot enzymes breaks down the

wound discharges and sloughs into end-products, which are then consumed by the maggots.

4. The therapeutic active principle of maggots stimulates rapid growth.

The beneficial effects (1) to (3) listed above can only be given by maggots themselves, while (4) could be given by allantoin. Thus, it is not difficult to see why maggot therapy does not necessarily equal allantoin therapy.

#### ALLANTOIN THERAPY

The synthetic allantoin has been mainly used in the form of a saturated solution (0.5 per cent at normal temperatures) or in the form of an ointment (2 to 5 per cent in a greaseless base).<sup>9</sup>

Almost all cases treated were those suffering from severe ulcers, suppurative wounds and osteomyelitis, and considerable success was claimed, although adequate testing and controls have not been carried out.<sup>10,11,12,13,14</sup>

#### CELL PROLIFERANT ACTION OF ALLANTOIN

Most of the observations on the cell proliferant action of allantoin are qualitative in character, since they generally relate to the healing of wounds.

Attempts to demonstrate the cell proliferant action of allantoin using the methods of tissue culture have not met with significant success.<sup>15,16</sup>

Allantoin does not normally play an important role in human metabolism, and occurs only to a small extent in human urine. However, it occurs in much higher concentrations in the allantoinic fluid and in the urine of pregnant women.

It is the normal end-product of purine metabolism in many animals, e.g., dogs, and again occurs in higher concentrations in the allantoinic fluid. This association of allantoin and pregnant animals has again led to the inference that allantoin is closely associated with cell proliferation.<sup>17</sup> Robinson has suggested that allantoin actually re-enters the cell nucleus.

It has been suggested that one of the functions of allantoin is to cause phagocytosis. Berthelot and Bertrand<sup>18</sup> reported that allantoin could cause leucocytosis in guinea pigs, while Macalister<sup>19</sup> showed that oral administration of allantoin could increase the leucocyte count from 5 to 15 per cent. The successes he obtained with allantoin in the treatment of pneumonia were attributed to the increase in leucocytosis.


#### THE CHEMISTRY OF ALLANTOIN

Allantoin may be obtained by the alkaline oxidation of uric acid in the cold.

It is a white, crystalline substance, m.p. 238° C., and is soluble to the extent of 0.6 per cent in cold water, 0.2 per cent in alcohol and insoluble in ether. It is appreciably soluble in hot water and alcohol. It is readily

decomposed by alkali and strong acids to give a variety of products. The  $pH$  value of a saturated solution is 5.5, and it is recommended that the solution should be kept at a slightly acid  $pH$  value.

The constitution of allantoin has been shown to be



Examination of the above formula shows that it contains an asymmetric carbon atom (\*). The allantoin should therefore exist in two optically active forms, but early attempts to isolate these forms were, however, unsuccessful.<sup>20</sup>

However, dl allantoin was resolved by Fosse, Thomas and de Graeve,<sup>21</sup> who isolated the "l" form by treating the allantoin with an enzyme from soya which preferentially fermented the "d" form. The "d" form is probably the one that occurs naturally, and has now been isolated from calves' urine and certain plants by extraction methods avoiding all temperature rises.

The "d" and "l" forms are both readily racemised even by warming in aqueous solution. The ease of racemisation is now known to be the reason for the failure of the early attempts at separation. The ready racemisation is almost certainly due to a keto-enol tautomerism existing between the asymmetric carbon atom and the neighbouring keto group. In view of this tautomerism, in order to maintain optical activity, solutions should be kept at  $pH$  values slightly less than 7.

Allantoin is amphoteric forming salts with both acids and bases. Ammonium,<sup>22</sup> piperazine<sup>23</sup> and bismuth<sup>24</sup> allantoinates have been used therapeutically, but they offer no advantage over the allantoin itself.

#### CONCLUSIONS

By analogy with other optically active systems, there should be a biological difference between "d" and "l" allantoin on the one hand as well as between them and racemic allantoin on the other. It is apparently the "d" form which normally functions in the living plant and animal. When racemic allantoin is applied therapeutically, it may be presumed that only one-half of it is active, while the other half may be inert or could even be in part an inhibitor or poison. No practical work has, however, been done on this aspect of allantoin therapy. However, it is almost certain that the allantoin in the extract of comfrey would be racemic, since the extract was obtained with the aid of heat.

The latest use of allantoin has been in association with the sulphanilamide drugs, where it has been used in cases of impetigo, dermatophytosis, pyoderma,

folliculitis.<sup>25</sup> Two cases of seborrhoeic dermatitis have been treated with this system.<sup>25</sup> The secondary symptoms of the latter, due to infection, were cleared within three weeks. Other uses for this combination have been in the preparation of wounds for skin grafting and in controlling wound infections.

In this combination can be seen a similarity to maggot therapy in that the sulphanilamide provides the bactericidal properties normally provided by the maggots, which are absent when allantoin alone is used.

It can be seen from the above account that the work reported on allantoin therapy is somewhat unlikely to be of great use in the cosmetic industry unless its alleged properties are more firmly established than hereto. It is of interest to note that allantoin is omitted from the latest editions of the *Pharmacopoeia*.

The author wishes to thank the directors of County Laboratories Ltd. for their permission to publish this paper.

#### REFERENCES

- <sup>1</sup> Macalister, *B.M.J.*, 1912, i, 10.
- <sup>2</sup> Macalister, *The Symphytum Officinale and Its Contained Allantoin*, John Bale, Sons & Danielsson Ltd., London, 1936.
- <sup>3</sup> Baer, *J. Bone & Joint Surgery*, **13**, 438 (1931).
- <sup>4</sup> Robinson, *J. Bone & Joint Surgery*, **17**, 267 (1935).
- <sup>5</sup> Robinson and Norwood, *J. Lab. & Clin. Med.*, **19**, 581 (1933-34).
- <sup>6</sup> Robinson and Norwood, *J. Bone & Joint Surgery*, **15**, 409 (1933).
- <sup>7</sup> Livingston, *J. Bone & Joint Surgery*, **18**, 751, (1936).
- <sup>8</sup> Livingston, *Am. J. of Surgery*, **35**, 554 (1937).
- <sup>9</sup> Greenbaum, 1938, U.S. Pat. 2,124,295.
- <sup>10</sup> Bethune, *J. Thoracic Surgery*, **5**, 322 (1936).
- <sup>11</sup> Gordon, *Intern. J. Orthodontia*, **23**, 840 (1937).
- <sup>12</sup> Kaplan, *J.A.M.A.*, 168 (1937).
- <sup>13</sup> Greenbaum, *J. Am. Pharm. Assn., Sci. Ed.*, **31**, 263 (1942).
- <sup>14</sup> Sussman, *Dental Items of Interest*, **59**, 510 (1937).
- <sup>15</sup> Shipp and Hetherington, *Proc. Soc. Exp. Biol. and Med.*, **35**, 180 (1936-37).
- <sup>16</sup> Pomerat, *Proc. Soc. Exp. Biol. and Med.*, **51**, 345 (1942).
- <sup>17</sup> See (2).
- <sup>18</sup> Berthelot and Bertrand [see (2)].
- <sup>19</sup> See (2).
- <sup>20</sup> Mendel and Dakin, *J. Biol. Chem.*, **7**, 153 (1909).
- <sup>21</sup> Fosse, Thomas and deGraeve, *C.R.*, **198**, 689 (1934).
- <sup>22</sup> Robinson and Spring, 1942, U.S. Pat. 2,303,765.
- <sup>23</sup> Greenbaum, *J. Am. Pharm. Assn., Sci. Ed.*, **31**, 263 (1942).
- <sup>24</sup> Engels, Rahway and Stein, U.S. Pat. 2,104,738.
- <sup>25</sup> Niedelman and Horoschok, *Urolog. & Cutan. Rev.*, **48**, 172 (1944).